Streetbeat News

Products Services

TECH

Bio-Techne and Novomol-Dx have developed Bio-marker Pathfinder, an ocular biomarker kit for point-of-care applications, utilizing Bio-Techne's Ella platform and Novomol-Dx's proprietary algorithms. The kit, aimed at diagnosing and monitoring conditions like Dry Eye Disease and Diabetic Retinopathy, promises accurate and fast results.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 11:12 am

IYT

JETS

LUV

Southwest Airlines Co (NYSE:LUV) is considering abandoning its open seating policy for assigned seats and premium options to attract younger travelers. This marks a significant shift from its traditional model since 1971. The decision is part of a broader strategy to meet evolving customer expectations, with an official announcement expected in September. Additionally, Southwest announced the closure of operations at four airports. The company's stock has declined over 11% in the past year, impacting investors in LUV and related ETFs like U.S. Global Jets ETF (NYSE:JETS) and iShares U.S. Transportation ETF (BATS:IYT).

Portfolio Pulse from Shivani Kumaresan

April 26, 2024 | 11:12 am

SATS

EchoStar Corporation announced that its subsidiary, Hughes Network Systems, has opened a new manufacturing facility and private 5G incubation center in Germantown, Maryland. This move aims to boost local talent and expand the company's capabilities in the 5G domain.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 11:11 am

CHTR

Charter Communications reported a decrease of 72,000 in total residential and SMB Internet customers, totaling 30.5 million as of March 31, 2024. Conversely, their mobile lines saw an increase of 486,000, reaching 8.3 million. Overall, Charter had 32.0 million residential and SMB customer relationships, excluding mobile-only relationships.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 11:08 am

CHTR

Charter Communications reported a decrease of 72,000 in Q1 residential and SMB Internet customers, but saw an increase of 486,000 in mobile lines. Total revenue for the quarter was $13.7 billion, a 0.2% increase year-over-year, with significant growth in residential mobile service and Internet revenue.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 11:06 am

BMY

Bristol Myers announced that the EMA's CHMP has recommended the approval of Opdivo in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. The European Commission will review the recommendation, with a final decision expected in June 2024.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 11:04 am

PFE

Pfizer's BEQVEZ, a one-time gene therapy for adults with Hemophilia B, has received U.S. FDA approval. Pfizer plans to launch an innovative warranty program for BEQVEZ, ensuring financial protection and maximizing access for eligible patients. BEQVEZ is also under review in Europe and has been approved in Canada. Pfizer is further investigating gene therapies for hemophilia A and Duchenne muscular dystrophy, and a treatment for hemophilia A and B, marstacimab, is under review by the FDA and EMA.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 10:48 am

NXT

Nextracker and JM Steel, a subsidiary of Jennmar Holdings, have completed a significant expansion of Nextracker-dedicated manufacturing lines at JM Steel's Leetsdale Steel Facility, reaching a capacity of 4 GW. This expansion is part of Nextracker's broader effort, marking 20 new or expanded U.S. manufacturing partner facilities since 2021, enabling the company to supply over 25 GW of U.S. solar tracker capacity annually.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 10:39 am

OCGN

Ocugen announced its plans to present on its Modifier Gene Therapy Platform at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting. This presentation could highlight Ocugen's advancements in ophthalmology and potentially impact its visibility and credibility in the biotech and healthcare sectors.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 10:36 am

LIN

Linde has increased its production capacity at Mims by 50%, following a project in 2020 that doubled its output. This expansion will support the demand for oxygen, nitrogen, and argon across various sectors including healthcare, manufacturing, food processing, and water treatment.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 10:27 am